Per Ramløv I.
- Country
- Denmark
- Department
- #4003: Nyremedicinsk Forskning, Nyresygdomme
Research Overview
- A Phase 3 open-label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in the treatment of severe anti-GBM antibody disease (Goodpasture disease)
- A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis (IC-MPGN)
- Long-term Safety and Tolerability Evaluation of Open-label Iptacopan in Adult Patients with Primary IgA Nephropathy: A Rollover Extension Program
Data & Insights
Has run more than one trial at 66 of 165 partner sites.
Specializations
Glomerular Diseases
This investigator specializes in treating various forms of glomerulonephritis, with particular focus on IgA nephropathy and its innovative therapeutic approaches. Their research encompasses both established and experimental treatments for glomerular conditions.
- Primary IgA Nephropathy Management
- Rapidly Progressive Glomerulonephritis Treatment
- Anti-GBM Antibody Disease Interventions
Autoimmune Disorders
The investigator demonstrates significant expertise in treating complex autoimmune conditions affecting the kidneys, particularly focusing on ANCA-associated vasculitis and systemic lupus erythematosus.
- ANCA-Associated Vasculitis Therapy
- Lupus Nephritis Treatment
- Goodpasture Disease Management
Innovative Therapeutics
This researcher explores cutting-edge therapeutic approaches including complement inhibition and cell-based therapies for treating various kidney diseases.
- Novel Complement Pathway Inhibitors
- Cellular Therapy Applications
- Targeted Immunological Interventions
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.